Author:
Pirkalkhoran Sama,Grabowska Wiktoria Roksana,Kashkoli Hamid Heidari,Mirhassani Reihaneh,Guiliano David,Dolphin Colin,Khalili Hanieh
Abstract
Antibody fragments are used in the clinic as important therapeutic proteins for treatment of indications where better tissue penetration and less immunogenic molecules are needed. Several expression platforms have been employed for the production of these recombinant proteins, from which E. coli and CHO cell-based systems have emerged as the most promising hosts for higher expression. Because antibody fragments such as Fabs and scFvs are smaller than traditional antibody structures and do not require specific patterns of glycosylation decoration for therapeutic efficacy, it is possible to express them in systems with reduced post-translational modification capacity and high expression yield, for example, in plant and insect cell-based systems. In this review, we describe different bioengineering technologies along with their opportunities and difficulties to manufacture antibody fragments with consideration of stability, efficacy and safety for humans. There is still potential for a new production technology with a view of being simple, fast and cost-effective while maintaining the stability and efficacy of biotherapeutic fragments.
Reference127 articles.
1. NCI Dictionary of Cancer Terms (2023, January 09). National Cancer Institute, Available online: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biological-drug.
2. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin;Itakura;Science,1977
3. Monoclonal antibodies with specificity for hairy cell leukemia cells;Posnett;J. Clin. Investig.,1982
4. Monoclonal antibody technology;Tami;Am. J. Health Pharm.,1986
5. Continuous cultures of fused cells secreting antibody of predefined specificity;Milstein;Nature,1975
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献